Target overview
Synonyms
CLDN18.2|Claudin 18.2|claudin18.2
Emerging Competitive
CLDN18.2 / Claudin 18.2
CLDN18.2 / Claudin 18.2 is flagged as emerging competitive based on 3 active trials across 6 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 6
Active trials: 3
Recruiting trials: 2
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 6
Top sponsors: Conjupro Biotherapeutics, . | LigaChem Biosciences, . | Evopoint Biosciences .
Tumor types: Pancreatic Cancer | Gastric Cancer | Advanced Solid Tumors
Patent-density signal summary
Patent layer
Signal count: 0
Recent signals: 0
Top assignees: Unknown
Signal types: Unknown
Scores and labels
Deterministic summary
Clinical crowding: 3/5 (Elevated)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.